Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 7 (6), 4966-77

Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria

Affiliations

Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria

Carlo Catassi et al. Nutrients.

Abstract

Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts' recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation is performed using a self-administered instrument incorporating a modified version of the Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week challenge followed by a one-week washout of strict GFD and by the crossover to the second one-week challenge. The vehicle should contain cooked, homogeneously distributed gluten. At least a variation of 30% of one to three main symptoms between the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. The guidelines provided in this paper will help the clinician to reach a firm and positive diagnosis of NCGS and facilitate the comparisons of different studies, if adopted internationally.

Keywords: diagnosis; double-blind placebo-controlled challenge; gastrointestinal symptom rating scale; irritable bowel syndrome; non-celiac gluten sensitivity.

Figures

Figure 1
Figure 1
The numerical rating scale (NRS) used for rating the intensity of relevant items.
Figure 2
Figure 2
The flow diagram of the NCGS diagnostic process. GFD = gluten-free diet; A = product A (gluten or placebo); B = product B (placebo or gluten); E = evaluation (questionnaire). The evaluation is performed weekly during Step 1 and daily during Step 2.

Similar articles

See all similar articles

Cited by 82 PubMed Central articles

See all "Cited by" articles

References

    1. Sapone A., Lammers K.M., Mazzarella G., Mikhailenko I., Cartenì M., Casolaro V., Fasano A. Differential mucosal IL-17 expression in two gliadin-induced disorders: Gluten sensitivity and the autoimmune enteropathy celiac disease. Int. Arch. Allergy Immunol. 2010;152:75–80. doi: 10.1159/000260087. - DOI - PMC - PubMed
    1. Biesiekierski J.R., Newnham E.D., Irving P.M., Barrett J.S., Haines M., Doecke J.D., Shepherd S.J., Muir J.G., Gibson P.R. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am. J. Gastroenterol. 2011;106:508–514. doi: 10.1038/ajg.2010.487. - DOI - PubMed
    1. Junker Y., Zeissig S., Kim S.J., Barisani D., Wieser H., Leffler D.A., Zevallos V., Libermann T.A., Dillon S., Freitag T.L., et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J. Exp. Med. 2012;209:2395–408. doi: 10.1084/jem.20102660. - DOI - PMC - PubMed
    1. Volta U., Bardella M.T., Calabrò A., Troncone R., Corazza G.R. Study Group for Non-Celiac Gluten Sensitivity. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity. BMC Med. 2014;12 doi: 10.1186/1741-7015-12-85. - DOI - PMC - PubMed
    1. Catassi C., Gatti S., Fasano A. The new epidemiology of celiac disease. J. Pediatr. Gastroenterol. Nutr. 2014;59:S7–S9. doi: 10.1097/01.mpg.0000450393.23156.59. - DOI - PubMed

Publication types

Feedback